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The control of gene expression is pivotal in biology. It is 
accomplished by a large number of regulators, including 
transcription factors (TFs), that can modulate mRNA 
synthesis by directly interacting with regulatory genome 
sequences. The human genome contains about 20,000 
genes and an estimated 1,400 TFs [1]. Although much is 
known about the basic mechanics of transcription, little 
is known about how TFs function collectively in the 
context of intricate gene regulatory networks (GRNs) to 
achieve complex biological outputs during development 
and in physiology and disease.
Ideally, one would like to comprehensively map the 
binding of each TF within the genome and understand 
the effects that such interactions have on its target genes. 
Conversely, for each gene, one would like to know which 
TFs contribute to its expression and in which cells and 
under which circumstances this contribution occurs.
Over the past decade several high-throughput method o-
l o gies have been developed, standardized and imple-
mented to map GRNs, including computational reverse 
engineering (reviewed in [2,3]), chromatin immuno-
precipitation (ChIP) combined with microarrays (ChIP-
chip) or next generation sequencing (ChIP-seq) (reviewed 
in [4,5]), and yeast one-hybrid (Y1H) assays (reviewed in 
[6,7]). Each of these methods has inherent limitations, 
and therefore GRNs might miss interactions (false 
negatives) and contain interactions that are not ‘bio-
logically meaningful’ (false positives; Table 1). Deter-
mining the scale of these limitations has proven difficult, 
in part because it is challenging to define the term 
‘biologically meaningful’. For instance, interactions 
between genes and regulators are often deemed bio-
logically meaningful only if the expression of the gene 
changes following removal or reduction of the regulator, 
and/or if mutations in the gene and the regulator confer 
similar phenotypes. Here, I discuss methods that are used 
to identify interactions between genes and regulators and 
illustrate different levels of validation that can be used to 
obtain further support for these interactions. In addition, 
I argue that lack of validation does not necessarily signify 
irrelevance because validation assays each come with 
their own caveats, and their interpretation can be further 
complicated by mechanisms such as TF redundancy. 
Instead, results from many assays should be combined to 
generate increasingly comprehensive, high-quality net-
work models.
Gene regulatory networks
GRNs are graph diagrams that depict interactions 
between genes and their regulators (such as TFs). These 
interactions can indicate a regulatory relationship, and/
or can depict a physical interaction between a TF and a 
genomic DNA region associated with a particular gene. A 
genome-scale method used for inferring regulatory 
interactions is to computationally search transcriptomic 
data for correlations between gene and TF expression. 
This reverse engineering approach has been pioneered in 
yeast [8] and has also been applied to mammals [9,10]. 
ChIP starts with a protein and is an example of a TF-
centered (protein-to-DNA) method, whereas Y1H starts 
with a DNA fragment and can be referred to as a gene-
centered (DNA-to-protein) technique (reviewed in [6,7]). 
Both ChIP (for example, [11-16]) and Y1H assays (for 
example, [17-21]) have been successfully used in various 
systems and have each led to a wealth of data. Impor-
tantly, inferred regulatory relationships are not necessarily 
a result of direct physical interactions. Conversely, for 
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physical interactions between TFs and DNA, the regu-
latory consequence (repression or activation) is usually 
not known. Therefore, for optimal coverage and infor-
mation content, both types of approaches need to be 
applied and integrated.
What is ‘biologically meaningful’?
The quality of GRNs depends on the proportion of real 
interactions that are retrieved and the proportion of 
retrieved interactions that are real. For many scientists, 
interactions identified by high-throughput methods are 
deemed biologically meaningful (real) only if a regulatory 
and/or functional consequence is demonstrated, after 
which the interaction is considered ‘validated in vivo’. 
However, a lack of in vivo validation does not necessarily 
invalidate an interaction because: (i) in vivo validation 
methods have their own limitations; (ii) a TF binding 
event might have been attributed to the wrong gene - for 
instance, when a TF binds an enhancer far from a trans-
cription start site; and (iii) biological safety nets that 
buffer the loss of individual TFs can mask the effect of 
genuine DNA-TF interactions on gene expression.
Data quality: false negatives
To obtain a complete picture of gene regulation, it is 
important to detect all physical and regulatory inter-
actions that occur between genes and TFs. However, it is 
likely that the interaction networks that have been 
deline ated so far are incomplete because not all 
interactions can be detected by the method(s) used. 
There are several reasons why DNA-TF interactions can 
be missed (false negatives; Table 1). In computationally 
inferred GRNs, relationships can be missed when the 
required cut-off for correlation was set too high, when 
TFs do not change in expression in accordance with their 
target genes, or when the TF or its target is expressed at 
very low levels, thereby disabling detection of expression 
changes. With ChIP, the detection of interactions 
depends on the expression level, concentration and 
activity of the TF in the cell or tissue sampled, and the 
strength and accessibility of its binding sites (Figure 1). 
With ChIP-Seq, precipitated DNA frag ments are 
sequenced, and bound regions are ‘called’ by compiling 
all the reads that correspond to particular genomic DNA 
regions into ‘peaks’. Subsequently, cut-offs are selected 
somewhat arbitrarily to distinguish bound from unbound 
regions [22]. This will inevitably cause the strongest and/
or most well-represented (robust) inter actions to be 
considered at the expense of weaker inter actions that 
might just as likely be biologically meaning ful. Gene-
centered Y1H assays also miss DNA-TF inter actions. For 
instance, interactions with obligatory hetero dimers 
cannot be detected with the current con figura tions of the 
assay. In addition, TFs that require post-translational 
modification or a cofactor in order to bind DNA may not 
be retrieved. When cDNA libraries are screened, low-
abundance TFs have a high likelihood of being missed. 
This disadvantage has been partially alleviated by using 
directed Y1H assays in which TFs are tested one by one 
for their ability to bind to a particular DNA fragment 
[23]. Such clone-based assays, however, depend on clone 
resources such as the ORFeome [24,25], and TFs for 
which open reading frame clones are not available will 
obviously not be represented in these assays.
Data quality: false positives
False positives can be incorporated into GRNs and can be 
either technical or biological. Technical false positives are 
interactions that are sporadic in nature and cannot be 
repeated, even with the same assay with which they were 
originally retrieved. Obviously, any high-throughput 
method should avoid detecting spurious interactions by 
carefully optimizing and evaluating the robustness of the 
assay. Biological false positives are defined as interactions 
Table 1. Overview of commonly used techniques for gene regulatory network mapping and their advantages and 
limitations
Method Characteristics Advantages Limitations
Computational inference 
(reverse engineering)
Infers putative regulatory 
relationships from gene 
expression data
Fast; cheap The interactions predicted could be indirect (they do 
not have to reflect physical interactions); regulators that 
themselves do not change in expression will be missed; 
detection limits of mRNA measurements will affect GRN 
predictions (regulators or genes expressed at low levels will 
be missed)
Chromatin 
immunoprecipitation (ChIP)
Experimentally identifies physical 
interactions between TFs and 
DNA; TF-centered (protein-to-
DNA)
In vivo; can detect TF dimers 
and complexes
Condition-dependent interactions can be missed; needs 
high-quality, highly specific ChIP-grade antibodies; when a 
universal tag is used for immunoprecipitation, TF is usually 
overexpressed; peak calling required
Yeast one-hybrid (Y1H) Experimentally identifies physical 
interactions between DNA and 
TFs; gene-centered (DNA-to-
protein)
Heterologous; condition- 
and context-independent
TFs that require post-translational modifications 
before binding DNA will be missed; not yet suitable for 
heterodimers
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that are robustly detected but that are not biologically 
meaningful. In computationally derived GRNs spurious 
edges (regulatory interactions) can arise if both a TF and 
its inferred target are regulated by another TF that itself 
does not change in expression. In ChIP experiments, 
biological false positives might be obtained when the 
antibody is not exclusively specific for the TF that is 
being studied, or when a TF is overexpressed (for 
instance, from a transgene), and starts binding to lower 
affinity or non-specific sites. Furthermore, selecting a 
threshold that is too low when ‘calling’ interactions from 
a background of non-interacting fragments may result in 
the inclusion of false interactions. Y1H assays can 
retrieve interactions that do not occur in vivo when a TF 
binding site is available in the context of yeast chromatin 
but not in the organism from which the DNA fragment 
was cloned. TF levels in yeast are controlled by a yeast 
promoter and by the copy number of the TF-expressing 
plasmid, and it is possible that lower affinity DNA 
sequences are bound when TF levels are high.
Five levels of validation
There are five conceptual levels of validation of inter-
actions between genes and their regulators.
The first level is retesting interactions detected with the 
same experimental approach and reagents to minimize 
technical false positives. This can be done by retesting 
individual interactions, or by performing larger, genome-
scale experiments multiple times. For example, in ChIP 
assays, the DNA regions deemed bound by a TF are often 
confirmed by quantitative PCR of the ChIPped DNA. 
However, this only confirms that the DNA fragment was 
precipitated; it is not a retest of the ChIP assay itself. In 
Y1H assays, interactions retrieved can be confirmed in 
freshly grown yeast cells containing the ‘DNA bait’, using, 
for instance, a TF-encoding clone [26].
The second level is confirming an interaction with the 
same assay but using different reagents. Computationally 
inferred regulatory interactions can be assessed in an 
independent dataset, or with a different algorithm. ChIP 
interactions can be confirmed by using multiple anti-
bodies to the same protein [15,27]. The signal-to-noise 
ratio can also be improved by including control experi-
ments of samples in which the TF is removed or reduced 
[12]. In such experiments, DNA regions that are detected 
by ChIP both in wild-type and TF mutant or RNA 
interference (RNAi) samples can be considered false 
posi tives, and thresholds can be drawn accordingly. Y1H 
assays use two reporter genes that are integrated into 
different locations in the yeast genome, and only inter-
actions that result in the activation of both reporters 
should be considered, as they are basically detected twice, 
and therefore confirmed. In addition, independent ‘DNA 
bait’ strains and ‘TF preys’ from different clone resources 
can be used to confirm interactions.
The third level is detecting an interaction with a 
different assay of the same type. For instance, to validate 
computationally inferred regulatory interactions one can 
use RNAi of a TF and examine changes in the expression 
of its inferred targets in vivo. This approach has recently 
been used for a subset of regulatory relationships 
inferred to control the pathogenic response of murine 
dendritic cells [10]. Physical interactions detected by 
Y1H assays can be confirmed by ChIP and vice versa. For 
example, we have confirmed multiple Y1H interactions 
in Caeno rhabditis elegans and Arabidopsis thaliana 
Figure 1. The detection of physical interaction between a TF and a target gene depends on various parameters, including the expression 
level or concentration of the TF, the activity of the TF, the affinity of the binding site for the TF and the accessibility of the binding site in 
the context of chromatin. TFBS, transcription binding site.
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interactions by ChIP [17,21]. Additional support for 
physical inter actions identified either by Y1H assays or 
by ChIP can be obtained by identifying a putative TF 
binding site within the DNA fragment bound, either 
using motif prediction algorithms (for example, [28-30]) 
or by interrogating large TF binding site datasets (for 
example, [31-34]). In Y1H assays, the putative site can be 
deleted and inter actions with the mutant fragment can 
be examined. Loss of the DNA-TF interaction with the 
mutant fragment would confirm that the selected 
binding site is indeed correct [35].
The fourth level is observing an interaction in a differ-
ent type of assay, that is, a regulatory interaction is con-
firmed by a physical interaction or vice versa. An example 
of how the regulatory effect of physical DNA-TF inter-
actions can be examined in C. elegans is the generation of 
trans genic animals that express green fluorescent protein 
(GFP) under the control of the DNA fragment with which 
the physical interaction was detected, and subjection of 
these transgenic animals to RNAi of the relevant TF or 
crossing them into TF mutant animals [19,20,36]. An 
increase in GFP expression following reduction of the TF 
would indicate that the TF represses gene expression, 
whereas a decrease in GFP expression following TF 
reduc tion would indicate that the TF is an activator. 
Other methods used to determine target gene expression 
in mutant/RNAi animals include quantitative RT-PCR 
and expression profiling (for example, [17,37]).
The final level is observing that a TF and its target share 
functional roles in a biological process, or confer similar 
phenotypes when mutated and/or overexpressed. Such 
functional similarities can be uncovered by performing 
phenotypic experiments, or alternatively, correlations 
between functions can be investigated in silico using 
Gene Ontology [38] and KEGG databases [39]. It is likely 
that a complete correlation between a TF and its target 
genes in either a biological process or a phenotype occurs 
only in a minority of cases because networks are highly 
interconnected, and TFs often have multiple functions 
according to developmental, physiological or environ-
mental circumstances.
Limitations of DNA-TF validation: detection limits 
and interpretation
It is important to note that validation experiments are 
each subject to their own limitations and that a negative 
result need not invalidate the original interaction ob-
served. For instance, when RNAi is used to examine 
regulatory relationships between a gene and its putative 
regulators, off-target effects can complicate the inter-
pretation. Therefore, it is desirable to observe the same 
effect on target gene expression with multiple small inter-
fering RNAs (siRNAs) designed to target the same regu-
lator. In C. elegans, not every tissue is equally amenable 
to RNAi; for instance, most neurons are largely refractory, 
and interactions occurring there would wrongly be 
deemed not valid when analyzed by RNAi [40,41]. When 
validating Y1H interactions by ChIP, it is important to 
perform the experiment using samples that not only 
express the TF of interest, but also under conditions 
where the TF is active (Figure 1). An example that 
illustrates this concept is C. elegans DAF-16, a forkhead 
TF that is located in the cytoplasm in wild-type animals 
unless they are exposed to nutritional or environmental 
stress. In daf-2 mutants, however, DAF-16 aberrantly 
translocates to the nucleus and is constitutively active, 
and the daf-2 mutant background has therefore been 
used to identify an initial set of DAF-16-bound regions 
[12]. Some other TFs could truly be bound to DNA sites 
in vivo, but be functionally dormant until activation by a 
ligand or signaling pathway, and regulatory effects would 
only be detectable under activation conditions. Prior 
knowledge of TF expression [42,43] or activity will greatly 
facilitate the design of an appropriate in vivo experiment. 
For instance, we focused on animals in the dauer stage (in 
which their development is arrested) to validate inter-
actions between microRNA promoters and DAF-3, 
whose expression greatly increases in the dauer stage and 
which confers a dauer-related phenotype [19]. Finally, 
some TFs may affect the expression of their target genes 
in a tissue-specific manner, and some TFs can even 
function as both an activator and a repressor, depending 
on the circumstances. For instance, using a transgenic 
GFP approach, we found that the C. elegans nuclear 
hormone receptor NHR-45 activates the promoter of 
nhr-178 in some tissues and under some conditions, 
whereas it represses it in other tissues under other 
conditions [20]. This example highlights the complexity 
of gene regulation and the caution one should take when 
interpreting ‘whole animal’ validation assays, such as 
quantitative RT-PCR.
Limitations of DNA-TF validation
In the past few years, it has become clear that many 
physical interactions - for instance, those identified by 
ChIP - do not convey a detectable regulatory conse-
quence on their predicted target genes (for example, 
[44,45]). This could be because the regulatory conse-
quences were tested under conditions in which the TF is 
not active. Alternatively, the wrong gene could have been 
attributed to the binding event, or the loss or reduction 
of individual TFs could have been masked by TF 
combinatorics or redundancy.
Both TF redundancy and combinatorics are prevalent 
in GRNs (Figure 2). For instance, multiple TFs from the 
same family can act through a single binding site and 
function redundantly, so that loss of one TF is com-
pensated by another (Figure 2a). Such redundancy has 
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been shown in various systems and for various different 
TF families, including mammalian ETS proteins that 
were studied by ChIP [46] and C. elegans FLYWCH-type 
zinc fingers that were found by Y1H assays [36]. Loss of a 
TF can also be masked by combinatorics involving TFs 
from the same family (Figure 2b) or different (Figure 2c) 
families, in which each TF contributes only a small regu-
latory effect, and this can lead to apparent redundancy. 
Such built-in redundancy may be very useful for critical 
genes that need to be buffered to avoid detrimental 
phenotypic consequences of TF loss [47].
Physical interactions between TFs and genomic DNA 
fragments are often inferred to affect the gene that is in 
closest linear proximity to the binding event. For inter-
actions that occur close to a transcription start site, either 
in a gene promoter or just downstream in the transcribed 
region, this is a reasonable assumption. Interactions 
involving more distant DNA elements (such as 
enhancers), however, may not necessarily affect a nearby 
gene because the genome is not organized as a linear 
polymer, but rather is organized in three dimensions [48]. 
Studies using chromatin conformation capture tech-
niques [49] are providing insights into which genomic 
regions contact each other to form loops, potentially to 
bring together enhancers and gene promoters. Inte-
grating physical and regulatory interaction data with 
structural genome and DNA looping data will facilitate 
the further dissection of GRNs.
Conclusions
When is an interaction between a genomic DNA frag-
ment and a TF biologically meaningful? When the gene 
located closest to the binding event changes in 
expression following loss or reduction of the TF? When 
Figure 2. The regulatory effect of a TF on a target gene can be masked when the TF is mutated (loss of function) or when its levels are 
reduced by RNAi. Two mechanisms that explain such masking are (a) TF redundancy and (b,c) the combinatorial interactions between multiple 
TFs, either from (b) one family or (c) from different families. In any of these cases, loss of a single TF would have only modest effects on target gene 
expression. Similar shapes with different colors indicate members of the same TF family; different shapes indicate members of different TF families.
Wild type √ TF mutant/RNAi
(a) TF redundancy: one TF family member can buffer the loss of another
(b) TF combinatorics: multiple members of a family regulate a gene, and loss of only one has little effect
(c) TF combinatorics: different types of TF regulate a gene, and loss of a single TF has little effect
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the gene and the TF have the same phenotype? Clearly, 
the answers are not simple, and the assays used to 
validate interactions are not foolproof. However, when 
the methods used for GRN delineation are robust and 
technically sound, individual interactions should not be 
discarded when one or more validation methods fail to 
detect regulatory or phenotypic consequences, 
particularly in complex, whole organisms. Rather, 
multiple methods need to be com bined into increasingly 
integrated networks to attribute different degrees of 
confidence to each of the interactions observed.
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